| D14 | Using private pharmacies for decentralized distribution of antiretroviral therapy: early lessons from seven sub-Saharan African countries | E-poster | Adherence to HIV treatment |
| D15 | One size does not fit all: preferences for HIV care delivery among out-of-care people living with HIV in the United States | E-poster | Retention in HIV services |
| D20 | Effect of COVID-19 pandemic on antiretroviral treatment use for HIV in the United States, 2020 | E-poster | Adaptations of HIV treatment services during COVID-19 |
| D20 | Rapid rebound in HIV service utilization following initial interruptions to HIV prevention and treatment for key populations during COVID-19 in South Africa | E-poster | Adaptations of HIV treatment services during COVID-19 |
| D49 | Conclusion of the national transition to dolutegravir (DTG) formulations for adult first-line (1L) recipients of care in Malawi: early outcomes and practical lessons for low- and middle-income (LMIC) settings | E-poster | Monitoring and evaluation of treatment and care |
| A45 | Defining an adipose tissue single cell atlas to understand metabolic disease in HIV | On-demand oral abstract session | Co-morbidities: Non-communicable diseases |
| A9 | Mechanisms of residual immune activation in HIV-1 infected human lymphoid tissue ex vivo | On-demand oral abstract session | Systemic immune activation and inflammation |
| A45 | The association of cardiovascular risk factors and disease in people living with HIV in the UK: a retrospective matched cohort study | On-demand oral abstract session | Co-morbidities: Non-communicable diseases |
| A45 | Higher comorbidity and comedication burden in women and young people living with HIV | On-demand oral abstract session | Co-morbidities: Non-communicable diseases |
| A22 | STAT modulation as strategy to improve NK cell cytotoxicity against HIV and cancer | On-demand oral abstract session | Immunotherapy: Immune-Modifying Agents |